Allergan reported net earnings of $359.9 million attributable to the company under generally accepted accounting principals for the quarter ended June 30, according to a company release. This marks an increase of 21.8% over the $295.4 million from the same quarter in 2012.Product net sales for the quarter were $1.577 billion, an increase of 10.6% over the company’s $1.426 billion in product net sales during the same period last year.
Month: July 2013
TearLab sells $40.4 million in common stock
TearLab sold 2.99 million shares of common stock at $13.50 in a public offering ended July 30, according to a news release.Total gross sales amounted to approximately $40.4 million, of which TearLab will collect approximately $37.5 million in net proce…
Merck quarterly net income drops $887 million
Merck’s generally accepted accounting principals net income for the second quarter was $906 million, down from $1.79 billion in the same period last year, according to a company news release.Patent expirations and poor foreign exchange rates are partially responsible for Merck’s sales for the period falling to $11 billion, down 11% from $12.3 billion in the same quarter last year, the release said.
Improving results of cataract surgery by looking at outcomes important to patients
Special issue of Optometry and Vision Science focuses on patient-reported outcome measures Cataract surgery can lead to good results from a clinical standpoint yet have poor outcomes from the patient’s point of view, reports a study, “Analyzing Patient…
Age-Related Eye Disease Study 2 (AREDS2) Ancillary Spectral Domain Optical Coherence Tomography (A2A_SDOCT) Extension Study
Status: Recruiting,
Condition Summary: AMD; Age- Related Macular Degeneration
CHMP Backs Aflibercept (Eylea) for Visual Impairment Caused by CRVO
The therapeutic indications for aflibercept (Eylea, Bayer Pharma AG) should include treatment of visual impairment caused by macular edema secondary to central retinal vein occlusion in adults. International Approvals
AMA urges physicians to report conflicts of interest prior to Sunshine Act deadline
The Physician Payment Sunshine Act will require pharmaceutical and medical device companies to report on their interactions with physicians starting on Aug. 1, and the American Medical Association is urging physicians to report, update and correct their financial and conflict of interest disclosures.“The Sunshine Act affects all physicians with a current medical license and the changes are starting now,” Ardis Hoven, MD, president of the American Medical Association (AMA) stated in a press release. “Physicians should know that pharmaceutical and medical device companies must begin tracking and reporting information on (Read more...)
Schizophrenia affected by ‘poor ability to track moving objects’
Impaired eye movements could play a part in the symptoms of schizophrenia, according to a study published in the Journal of Neuroscience. Researchers form the University of British Columbia tracked the eye movements of patients with schizophrenia whil…
InnFocus gets financing FDA authorization for MicroShunt study
The U.S. Food and Drug Administration has granted authorization to InnFocus to begin a phase 1 trial of its MicroShunt device to treat open-angle glaucoma, according to a news release.InnFocus also received $13.4 million in financing from HOYA Group an…
Corneal sensitivity decreased in keratoconus patients after corneal cross-linking
Use of corneal cross-linking resulted in reduced corneal sensitivity among patients with progressive keratoconus, according to a study.The prospective, nonrandomized clinical trial included 72 eyes of 36 patients. Cross-linking surgery was performed on…
SD-OCT may predict disruption of segment layers for patients with commotio retinae
Spectral-domain optical coherence tomography predicted visual prognosis of commotio retinae, according to a study.The retrospective review included 52 eyes of 52 patients with outer retinal atrophy resulting from closed-globe trauma. The authors analyz…
Valeant to cut staff with Bausch + Lomb buyout
Upon completion of Valeant’s $8.7 billion buyout of Bausch + Lomb, the new organizational design is expected to reduce the workforce by 10% to 15% across the newly combined company, according to a letter to workers from Valeant CEO J. Michael Pearson. The letter was also filed with the U.S. Securities and Exchange Commission.Worldwide, Bausch + Lomb employs approximately 11,000 people, while Valeant employs approximately 7,500, according to their respective websites.
Vanderbilt offers first FDA-approved bionic eye for treatment of retinitis pigmentosa
Vanderbilt University Medical Center has been chosen as one of 12 sites in the United States to offer the first FDA-approved bionic eye for the treatment of retinitis pigmentosa (RP).
Nerve Disease of Eye Halted with Rituxan (CME/CE)
(MedPage Today) — Treatment of neuromyelitis optica with a personalized regimen of rituximab (Rituxan) was effective in long-term disease suppression, a retrospective Korean study found.
Manufacturers exceed $1 billion in payments to IRS from medical device tax
Medical device manufacturers recently surpassed $1 billion in payments to the Internal Revenue Service for the medical device excise tax, which went into effect on Jan. 1, according to a joint announcement from the Medical Imaging & Technology Alliance, Advanced Medical Technology Association and Medical Device Manufacturers Association. “The $1 billion threshold is frightening as every dollar spent paying for this medical device tax threatens medical innovation and American jobs,” Gail Rodriguez, executive director of the Medical Imaging & Technology Alliance (MITA), stated in a press release. “MITA is pleased (Read more...)
Smart, Continuous Monitoring of Intra-Ocular Pressure with Triggerfish Contact Lens: Q&A with René Goedkoop, CMO of Sensimed
Smart contact lenses are no longer science fiction. In the last few years we have covered several smart contact lenses with different purposes. One of these electronic contact lenses is the Sensimed Triggerfish, a device capable of continuous measurement of the intra-ocular pressure (IOP). It is the first of its kind, since current measurement (Read more...)
Spectral-domain OCT capable of identifying glaucomatous progression
Spectral-domain optical coherence tomography was useful for detecting progression in glaucomatous eyes through the serial measurement of parameters in circumpapillary retinal nerve fiber layer, macula and optic nerve head, according to a study.The long…
Ray tracing method yields superior toric IOL power calculations
A ray tracing method that utilized combined keratometry and anterior and posterior topography/tomography data in conjunction with toric aspheric lenses yielded superior predictive precision, researchers found.The study included 78 eyes of 56 patients w…
Anti-VEGF for submacular hemorrhage from AMD reduces lesions, improves vision
Anti-VEGF monotherapy improved visual and anatomic outcomes in the treatment of large sub-retinal hemorrhages attributed to neovascular age-related macular degeneration, according to a study.The retrospective study included 19 eyes of 18 patients with …
BLOG: Who has dry eye?
Now that you’ve decided you want to treat dry eye, you probably are wondering what you’ve gotten yourself into.The first thing to figure out is who has dry eye. It turns out that almost anyone can have what we know as dry eye, but there is one very common type of patient with whom you always need to be on the lookout for dry eye in all its forms.